Drugs / DW5124
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07319559 | May 2025 | hyperlipidemia, combined, 2 | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DW5124 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07319559 ↗ |